It’s important to take the time to read and understand the information presented in this article. Please share your thoughts and leave a comment.
What the evidence shows
Fenbendazole can interfere with cancer-cell growth and survival in laboratory experiments, and some mouse tumor studies report tumor suppression. Other animal studies have found no meaningful antitumor effect, including studies in which the same drug killed the cells in culture. The human literature includes reported tumor regressions during fenbendazole use, but the cases are uncontrolled and often involve other treatments. They do not establish that fenbendazole caused the regressions or that it is safe or effective for human cancer.
Fenbendazole is a veterinary antiparasitic; it is not approved for use in humans in the United States. In 2026, the American Society of Clinical Oncology (ASCO) advised against using it to treat cancer or supplement established therapy outside a well-designed clinical trial, citing the lack of established benefit and potential harms.
Scope: This is a broad evidence review, not a formal systematic review or an inventory of every social-media testimonial. It includes identified positive and negative preclinical experiments, published human case reports, selected public anecdotes, and reports of harm. Individual online accounts can be duplicated, incomplete, or unavailable for independent verification. Dates, diagnoses, prior treatments, and outcome claims below are attributed to their sources rather than independently confirmed unless noted.
What happens in cancer cells?
Cell killing and proposed mechanisms
Researchers have tested fenbendazole directly on cancer cells from several tissues. These experiments expose cells to a known concentration in a dish; they do not establish that the same exposure, duration, or response can be achieved safely in a person.
Lung and other cell lines: Dogra and colleagues reported that fenbendazole interacted with mammalian tubulin, killed human cancer cells at micromolar concentrations, and changed p53 localization, glucose uptake, and expression of glucose-related proteins. An earlier paper from the group reported proteasome impairment and cellular stress in human non-small-cell lung cancer cells. These are proposed mechanisms in the tested systems, not proof that all of them drive an anticancer effect in patients.
Colorectal cancer: In a study comparing SNU-C5 cells with a 5-fluorouracil-resistant derivative, fenbendazole reduced growth and induced cell-cycle arrest and cell death in both. The resistant cells required a higher concentration: the reported three-day half-maximal inhibitory concentrations were 4.09 µM versus 0.50 µM in the parental cells. Sensitivity in a dish is not evidence that fenbendazole overcomes chemotherapy resistance in patients.
Ovarian cancer: Fenbendazole reduced proliferation and increased apoptosis in human A2780 and SKOV3 cells. Reported 48-hour half-maximal inhibitory concentrations were 0.44 and 1.05 µM, respectively; the authors also observed mitotic abnormalities.
Breast cancer: One study found different sensitivities across breast cell lines after 48 hours: approximately 10 µM for MDA-MB-231 triple-negative cells, approximately 75 µM for MCF-7 cells, and more than 100 µM for the MCF-10A nonmalignant cell comparator. That selective pattern applies to the specific cells and assay tested, not to all breast cancers or normal tissues.
Cervical cancer and stem-like cells: A study tested HeLa and C-33 A cervical cancer cells and sorted CD133-positive/CD44-positive subpopulations described as stem-like. Fenbendazole reduced proliferation and induced cell-cycle arrest and apoptosis in the tested populations.
Lymphoma and liver cancer models: Fenbendazole reduced metabolic activity and induced cell-cycle changes in EL-4 mouse lymphoma cells. In rat H4IIE liver-cancer cells, it suppressed actively growing cells but had much less effect on confluent, relatively quiescent cells.
Other animal-derived cancer cells: Researchers also reported dose-dependent viability reductions in canine melanoma cell lines and cytotoxic effects in canine glioma cell lines. These are laboratory experiments on cells, not trials showing that dogs or people with cancer benefit.
Several mechanisms recur—microtubule disruption, altered cell-cycle progression, apoptosis, oxidative stress, and changes in glucose metabolism—but they are not uniformly observed. For example, the H4IIE study did not find changes in glucose consumption, lactate production, or reactive oxygen species under its conditions. It would therefore be too strong to say that fenbendazole reliably “starves cancer” or acts through one proven pathway across cancers.
What cell-study concentrations mean
A concentration that kills a cultured cell is not an established human dose. Exposure depends on absorption, metabolism, protein binding, drug distribution into tumors, and how long the concentration is maintained. One experimental pharmacokinetic analysis concluded that poor pharmacokinetic properties could limit systemic anticancer activity; that is a translational concern, not a definitive measurement of efficacy in human cancer. Human liver microsome work has investigated enzymes that metabolize fenbendazole, but this is not a clinical dosing study.
What happened in animals?
Studies reporting tumor suppression
Human lung cancer xenografts. Dogra and colleagues reported inhibited growth of human cancer xenografts in immunodeficient mice given oral fenbendazole. This is a positive animal signal, but a xenograft in a mouse is not a human clinical response.
Human ovarian cancer xenografts. Researchers reported smaller, lighter SKOV3-derived tumors in mice treated orally with fenbendazole compared with controls. The same study found activity against A2780 and SKOV3 cells in culture. The accessible text did not establish all details needed here to assess the animal comparison, including group size.
Human cervical cancer xenografts. In a HeLa xenograft experiment, tumor-bearing mice were randomized to four groups; the study allocated five mice per group to tumor/tissue analysis and five to survival observation. The higher fenbendazole dose tested significantly reduced tumor weight compared with the model group; the lower dose did not meet that comparison’s significance threshold. This is an interesting but small experiment, and the survival results should not be interpreted as a prediction for women with cervical cancer.
Mouse mammary tumors. A 2025 study reported reduced tumor volume and weight in an EMT6 mouse mammary-cancer model, with five mice per group. The authors investigated a cell-death pathway involving caspase-3 and GSDME and reported no significant body-weight difference between treated and control mice. These measurements do not establish human safety.
Fenbendazole plus another experimental compound. In mice carrying human A549 lung-cancer xenografts, a combination of fenbendazole and diisopropylamine dichloroacetate produced greater reported tumor suppression than single-agent groups. This does not establish a fenbendazole-alone effect, clinical synergy, or protection against liver injury in humans.
Studies that did not show a fenbendazole-alone benefit
Mouse mammary cancer: negative results despite cell killing.
Duan and colleagues found that intensive fenbendazole exposure killed EMT6 cells in culture, but their tested regimens did not slow EMT6 tumors in mice or improve the antitumor effect of radiation. A related study found that fenbendazole-containing feed did not alter EMT6 tumor growth, invasion, metastasis, or radiation-associated growth delay.
This contrasts with the 2025 positive EMT6 study described above. Both matter: differences in study methods, formulations, schedules, tumor handling, and other conditions may affect results, but the available comparison does not establish which difference explains the discrepancy. The literature does not support treating either outcome as a guaranteed effect in every model.
Mouse lymphoma: cells responded, tumors did not. In the EL-4 mouse lymphoma model, fenbendazole reduced cell viability in culture but tumor growth in treated mice was comparable to controls; a chemotherapy comparator reduced tumor weight. The authors also reported weakness and changes in the tumor immune environment, whose cause and clinical significance were uncertain.
Lymphoma xenografts and vitamins. A 2008 experiment assigned 20 mice to four diet groups before human lymphoma implantation. Fenbendazole alone and vitamins alone did not alter tumor growth compared with control; the combination was associated with significant inhibition. That finding is not evidence that fenbendazole alone works, nor that taking vitamins with it is safe or effective in people.
A different concern: liver tumor-promotion markers
An older rat experiment examined liver changes after exposure to a carcinogen followed by fenbendazole-containing feed. At high dietary exposures, the researchers observed changes in liver enzymes and markers associated with tumor promotion, including increased numbers of certain altered cells and mini-foci. This was a short-term marker study, not a demonstration that fenbendazole causes liver cancer in people or a test of cancer treatment. It is nevertheless a reason not to presume that all biological effects are beneficial.
Human reports and anecdotes
Joe Tippens: the widely shared lung-cancer story
Joe Tippens publicly attributed his remission from metastatic small-cell lung cancer to fenbendazole. Reporting on his story also notes that he received an experimental cancer drug and supplements; a medical commentary describes him as participating in a clinical trial while using fenbendazole. The account is important because it prompted interest and self-treatment, but the available report does not isolate which intervention or combination caused his outcome. It should not be dismissed as an experience, or presented as proof of a cure.
An individual lymphoma report
In a 2020 case report, an 83-year-old man with stage IV diffuse large B-cell lymphoma declined chemotherapy and took fenbendazole after his own research. The report describes smaller lymph nodes and subsequent imaging improvement; it does not establish complete eradication or causation. He reduced his use after developing peripheral neuropathy, although a single report cannot determine whether the drug caused it. This is a noteworthy reported regression without the same concurrent chemotherapy confounding as some other anecdotes, but diagnosis verification, the complete treatment history, alternative explanations, and reproducibility remain essential to interpretation.
Three genitourinary cancer reports
A 2021 case series described three people with reported radiographic responses after fenbendazole use. It is a case series, not a prospective trial or a validated “Stanford protocol”:
Kidney cancer: A man with recurrent or metastatic renal cell carcinoma experienced substantial imaging improvement after starting fenbendazole around the time he received nivolumab. Nivolumab is a major alternative explanation; the authors acknowledged that the response could have occurred without fenbendazole.
Urethral cancer: A man with metastatic urethral cancer had a previously enlarging lymph node shrink during use of fenbendazole, vitamin E, curcumin, and CBD, after several earlier cancer treatments. No new systemic therapy was initiated during the described interval. This case warrants attention but cannot distinguish the contributions of the multiple agents, prior therapies, or other factors.
Bladder cancer: A woman had no evident disease on follow-up imaging after tumor resection and multi-agent chemotherapy given concurrently with fenbendazole. The established treatments are major competing explanations.
The series reported no adverse effects attributed to fenbendazole, but three selected cases are too few and too uncontrolled to demonstrate safety.
A retracted breast/prostate/melanoma series
A 2025 article described reported responses in three people with breast cancer, prostate cancer, or melanoma who used fenbendazole alongside other therapies. The journal retracted the article in January 2026. The retraction statement identified an undeclared potential conflict of interest involving services offered by the first author and said the editor considered the concern consequential for interpretation. It did not say the individual cases were fabricated; it means the article should not be relied upon as established clinical evidence. Concurrent treatments also prevent attributing the reported responses to fenbendazole.
Other online reports and the broader picture
There are online testimonials involving pancreatic, breast, and other cancers, often describing fenbendazole alongside ivermectin, supplements, chemotherapy, surgery, or other interventions. For example, one public account reports pancreatic imaging and biomarker improvement after a multi-agent regimen and earlier chemotherapy; the account does not independently establish the drug’s contribution. Such reports may be useful leads for obtaining consented medical records and complete timelines, but a collection of favorable testimonials without a defined denominator cannot estimate response rates or prove effectiveness.
A retrospective single-institution conference abstract identified 182 patients who self-reported fenbendazole use over its stated review period. It describes use patterns rather than a controlled test of efficacy or safety; it should not be read as 182 successfully treated cases.
Human safety: the evidence is not just theoretical
Lung cancer and liver injury: An 80-year-old woman receiving pembrolizumab self-administered fenbendazole and developed severe liver injury. Liver tests improved after fenbendazole was stopped, and pembrolizumab was later restarted without a recurrence of liver dysfunction. The case report noted no tumor shrinkage during the fenbendazole period. Other causes and interactions cannot be excluded with certainty in a single case.
Metastatic colon cancer: A 2026 case report described severe liver injury after a patient increased self-administered fenbendazole while receiving nivolumab/relatlimab. The authors considered fenbendazole a probable cause; tests improved after stopping it, and immunotherapy was restarted without recurrence. This temporal pattern strengthens suspicion but does not establish an incidence rate.
Prostate cancer: A man taking veterinary fenbendazole and ivermectin developed severe liver injury that improved after both were stopped. Because he took both agents, the report cannot establish which one was responsible.
Biopsy-confirmed injury: A separate report described severe liver injury associated with self-administered fenbendazole in a woman who was not presented as a cancer-treatment efficacy case; liver tests normalized after cessation.
The reports cannot tell us how commonly liver injury occurs or identify a safe cancer dose. They do establish a clinically relevant warning signal. Fenbendazole metabolism may also complicate the assessment of interactions with cancer medicines; specific interaction risks remain uncertain.
What would resolve the uncertainty?
A credible development program would first establish a suitable human-grade formulation, exposure and metabolism, interactions, and tolerability. It would then need a prospective cancer study with defined eligibility, independently reviewed imaging, complete recording of previous and concurrent treatment, systematic adverse-event monitoring, and an appropriate comparator. Animal models should include both positive and negative findings, and proposed combinations should be tested against each component separately.
For someone considering fenbendazole now, the clinically important step is to tell the oncology team exactly what has been taken, including veterinary products and supplements. Do not replace or delay established treatment based on a case report. ASCO recommends against use for cancer outside a well-designed clinical trial.
Sources
Wang et al., 2024. Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study. BMC Cancer.
Duan et al., 2013. Fenbendazole as a Potential Anticancer Drug. Anticancer Research.
Jung et al., 2023. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology.
Ryan S Chiang, 2020. Fenbendazole Enhancing Anti-Tumor Effect: A Case Series.
ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials | ASCO Connection, 2026.
Dogra et al., 2018. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports.
Park et al., 2022. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean Journal of Physiology and Pharmacology.
Dogra & Mukhopadhyay, 2012. Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells. Journal of Biological Chemistry.
Semkova et al., 2023. Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells. Anticancer Research.
Lei et al., 2025. Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer Through Dual Targeting of Cancer Cells and Cancer Stem Cells: Evidence from In Vitro and In Vivo Models. Molecules.
[Jung et al., 2023. Differential cytotoxic effects of fenbendazole on mouse lymphoma EL-4 cells and spleen cells. Korean Journal of Veterinary Research.
Park, 2022. Fenbendazole Suppresses Growth and Induces Apoptosis of Actively Growing H4IIE Hepatocellular Carcinoma Cells via p21-Mediated Cell-Cycle Arrest. Biological and Pharmaceutical Bulletin.
Kim et al., 2022. G2/M arrest and mitotic slippage induced by fenbendazole in canine melanoma cells. Veterinary Medicine and Science.
Lai et al., 2017. In vitro anti‐tubulin effects of mebendazole and fenbendazole on canine glioma cells. Veterinary and Comparative Oncology.
Jang et al., 2022. Investigation of benzimidazole anthelmintics as oral anticancer agents. Bulletin of the Korean Chemical Society.
Wu et al., 2013. CYP2J2 and CYP2C19 Are the Major Enzymes Responsible for Metabolism of Albendazole and Fenbendazole in Human Liver Microsomes and Recombinant P450 Assay Systems. Antimicrobial Agents and Chemotherapy.
Pan et al., 2025. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway. Frontiers in Pharmacology.
Thai Q Nguyen, 2025. Synergistic anti-tumor effect of fenbendazole and diisopropylamine dichloroacetate in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells - PMC.
Duan et al., 2012. Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies. Journal of the American Association for Laboratory Animal Science.
Gao et al., 2008. Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science.
Shoda et al., 1999. Liver Tumor Promoting Effects of Fenbendazole in Rats. Toxicologic pathology (Print).
Kertscher, 2023. PolitiFact | No proof that the dog deworming drug fenbendazole can cure human cancer.
Heo, 2020. Anthelmintics as Potential Anti-Cancer Drugs? - PMC.
Fenbendazole as a Treatment for Diffuse Large B-Cell Lymphoma.
William Makis, 2025. Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients - PMC.
Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients” [Case Rep Oncol. 2025;18:856–863; https://doi.org/10.1159/000546362] - PMC, 2026.
Anane. VERMECTIN and FENBENDAZOLE Case Report – 67-Year-Old Woman with Stage 4 Pancreatic Cancer Achieves Complete Remission After Failing Chemotherapy – Metabolic Oncology Research LLC.
Olutayo et al., 2026. A single institutional experience on patterns of ivermectin and fenbendazole use among patients with gastrointestinal cancers. Journal of Clinical Oncology.
Teppei Yamaguchi, 2021. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information - PMC.
Krishnan et al., 2026. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis - the importance of structured causality assessment: A case report. World Journal of Clinical Cases.
Grace Powderly, 2026. Drug-Induced Liver Injury Following Co-ingestion of Veterinary Fenbendazole and Ivermectin for Prostate Cancer: A Case Report.
Aishwarya Thakurdesai, 2024. Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole - PMC.